



offset project CRO_A-00033 "Technology & Know-how Transfer in Metabolomics and Establishment of Latest Scientific Equipment in Zagreb"



Genomski i glikanski biomarkeri
PTSP-a -GlikoGenPTSP
IP-2014-09-4289

METABOLOMSKA I GLIKOMSKA ISTRAŽIVANJA U PTSP-U


DR. SC. DUBRAVKA ŠVOB ŠTRAC, VIŠA ZNANSTVENA SURADNICA
LABORATORIJ ZA MOLEKULARNU NEUROPSIHIJATRIJU
INSTITUT RUĐER BOŠKOVIĆ

Posttraumatski stresni poremećaj (PTSP)


- anksiozni (ili stresom uzrokovani) poremećaj koji nastaje nakon izlaganja ili svjedočenja teškom traumatskom događaju kod nekih, ali ne svih osoba

Kriteriji DSM-V (APA, 2013):


- postojanje traumatskog iskustva
 - ponovno proživljavanje traume (eng. *reexperiencing*)
 - izbjegavanje (eng. *avoidance*)
 - pojačana pobuđenost (eng. *hyperarousal*)
 - neosjetljivost (eng. *numbing*) i negativne promjene mišljenja i raspoloženja
 - trajanje (najmanje 1 mjesec)
 - znatan poremećaj u radnom, socijalnom ili drugom funkcioniranju



PTSP u društvu



Opća populacija 7-12%



Hrvatski branitelji 25-30%

značajno narušeno psihičko, socijalno i radno funkcioniranje

➤ agresivno ponašanje, zloporaba alkohola i droga, suicidalnost

često prisutni i drugi psihopatološki komorbiditeti

➤ veliki depresivni poremećaj, anksiozni poremećaji, panični poremećaj, poremećaj ličnosti, alkoholizam, suicidalnost...

često prisutni somatski komorbiditeti


➤ kardiovaskularne bolesti, koronarna bolest srca, endokrine bolesti, metabolički sindrom, respiratorne bolesti, probavni poremećaji

40% oboljelih od PTSP-a ne pokazuje dobar odgovor na terapiju




Rizični čimbenici za razvoj PTSP-a

- doživljaj traume
- težina i vrsta traume
- spol
- komorbidne bolesti
- genetski i epigenetski čimbenici
- neurobiološki i psihološki čimbenici
- okolišni čimbenici
- izloženost ranoj traumi



Neurobiološke i neuroendokrinološke promjene u PTSP-u


- kao odgovor na traumu amigdala stimulira simpatički živčani sustav i os HHN




Poremećena neuroendokrinologija i os HHN

- ↑ CRF
paradoksalno ↓ aktivnost osi HHN
- ↓ kortizol u 24h urinu
kortizol u serumu
- hipersupresija nakon DST-a
- ↓ mehanizam negativne povratne sprege
- ↑ broj receptora za GK u limfocitima
- ↓ volumen hipokampusa
teškoće pamćenja
- poremećaji neurotransmisije


Glikani



- oligosaharidni lanci kovalentno vezani na polipeptide i lipide
- mijenjaju fizikalno-kemijska svojstva i biološku ulogu proteina
- modifikacija proteina u endoplazmatskom retikulumu i Golgijevom aparatu
- poveznica genetičke upute i okolišnih čimbenika → adaptacija
- N-glikani i O-glikani



Gotovo sve interakcije na površini stanice uključuju glikane



Uloga glikana u:

- međustaničnoj komunikaciji
- signalizaciji
- smatanju proteina
- regulaciji ekspresije gena
- diferencijaciji
- razvoju
- upalnim procesima
- metastaziranju...

Promjene u glikozilaciji

➤ u neuropsihijatrijskim poremećajima: ADHD, Alzheimerovo bolesti, autizmu, shizofreniji...

JOURNAL OF PROTEOMICS 75 (2012) 5123–5139

Available online at www.sciencedirect.com

SciVerse ScienceDirect

www.elsevier.com/locate/jprot

 ELSEVIER

Review

Glycomics of pediatric and adulthood diseases of the central nervous system

Rita Barone^{a,1}, Luisa Sturiale^{b,1}, Angelo Palmigiano^b, Mario Zappia^c, Domenico Garozzo^{b,*}

Molecular & Cellular Proteomics 10.1

Research

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at <http://www.mcponline.org>

Human Plasma Glycome in Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorders*

Nela Pivac^{†,d}, Ana Knežević^d, Olga Gornik[§], Maja Pučić[¶], Wilmar Igl^{||}, Hilde Peeters^{**}, An Crepel^{**}, Jean Steyaert^{**}, Mislav Novokmet[¶], Irma Redžić[§], Matea Nikolac[‡], Vesna Novković Hercigonja^{‡‡}, Katarina Dodig Čurković^{§§}, Mario Čurković^{¶¶}, Gordana Nedić[‡], Dorotea Muck-Seler[‡], Fran Borovečki^{|||}, Igor Rudan,^{ab} and Gordan Lauc^{§¶}

Alzheimer's Disease

Serum: decrease of digalactosylated core- α -1,6-fucosylated biantennary glycan. Increase of α 1,3-fucosylated trigalactosylated glycans. [patent application publication, May 5, 2011].

CSF: altered levels of full-length Reelin and Reelin 180 kDa fragment. Abnormal glycosylation pattern of 180-kDa reelin [26]. Increase of sialylated O-glycans in Tyr10 of APP/A β glycopeptides [23]. Decrease of TTR brain-specific isoform [76]. Quantitative changes of apolipoprotein E, clusterin, α -1- β -glycoprotein and α -1-AAT. Decreased glycosylation of one specific α -1-antitrypsin isoform [80,82]. Decrease of WGA-reactive Tf glycoforms [88,89].

Idiopathic normal pressure hydrocephalus

CSF: increase of Tf-2 (serum type)/Tf-1 (brain-type) glycoforms ratios
Multiple sclerosis

Serum: modification of plasma acute-phase proteins glyco-isoforms
Schizophrenia

Serum: increase in male patients of tetraantennary tetrasialylated glycans bearing polygalactosamine with A4G4LacS4 extension and triantennary trisialylated containing the SLe x epitope [105].

CSF: decrease of bisecting and sialylated glycans levels.

ADHD Plasma: ↑ in glycan groups GP11 and DG7 and ↓ in GP12

Serum: increased antennary fucosylation of biantennary glycans and decreased levels of some complex glycans with three or four antennas

N-glikani u PTSP-u

OPEN

Citation: *Transl Psychiatry* (2013) 3, e320; doi:10.1038/tp.2013.93
© 2013 Macmillan Publishers Limited All rights reserved 2158-3188/13
www.nature.com/tp




ORIGINAL ARTICLE

N-glycosylation profiling of plasma provides evidence for accelerated physiological aging in post-traumatic stress disorder

M Moreno-Villanueva^{1,7}, J Morath^{2,7}, V Vanhooren^{3,4}, T Elbert², S Kolassa⁵, C Libert^{3,4}, A Bürkle¹ and I-T Kolassa^{2,6}



PTSP



Peak1=FA2 - agalactosylated core-a-1,6-fucosylated biantennary


Peak6=FA2G2 - bigalactosylated core-a-1,6-fucosylated biantennary; NA2F

- testirali 9 N-glikanskih struktura iz plazme na 13 ispitanika s PTSP-om, 9 ispitanika koji su bili izloženi traumi i 10 kontrolnih ispitanika
- koncentracija N-glikana se mijenja s dobi

GlycoAge Test: = $\log_{10}(\text{FA2}/\text{FA2G2})$
daje predodžbu o stvarnoj dobi ispitanika


HrZZ projekt : Genomski i glikanski biomarkeri PTSP-a

GlikoGenPTSP (voditelj: prof. dr. Nela Pivac)



Cilj istraživanja:


- ispitati razlike u glikozilaciji kod osoba s dijagnosticiranim PTSP-om ($N=350$) i zdravih kontrolnih ispitanika ($N=350$) određivanjem N-glikana u plazmi i vezanih na IgG
- ispitati postoji li povezanost određenih genetskih polimorfizama i epigenetskih modifikacija s glikomskim promjenama i shodno tome povećanim rizikom za razvoj PTSP-a



Materijali i metode

Ispitanici: Klinika za psihijatriju Vrapče , Zagreb

- osobe s PTSP-om (N=204): DSM-IV (SCID, CAPS)
- zdrave kontrole (N=134)
- ispitanici su muškarci (prosječna dob: 56 god.) hrvatskog podrijetla, koji nisu u međusobnom srodstvu




Obrada N-glikana: Laboratorij za glikobiologiju, Genos d.o.o, Zagreb

- visokotlačna tekućinska kromatografija (HPLC) fluorescentno obilježenih N-glikana za kvantitativnu analizu glikoma u plazmi i vezanog za IgG
- naša studija obuhvaća 39 N-glikanskih pikova iz plazme i 24 N-glikanska pika vezana za IgG


Rezultati

N-glikani u plazmi:




GP14, **GP15**, GP26, GP27, GP30,
GP32, GP33, **GP34**, GP35, **GP36**,
GP37, **GP38**, GP39

PTSP



GP4, **GP5**, **GP10**, GP13, GP16,
GP19, **GP22**, GP29




- snažan utjecaj dobi na razinu N-glikana → korekcija ($p=0,05$; korekcija na višestruko testiranje: $p=0,001^*$)

Rezultati

N-glikani u plazmi:




p=0,001




GP15 = A2BG2S1 - biantennary bigalactosylated and sialylated with bisecting GlcNAc

p=1,56E-4




GP32 = A3F1G3S3 – triantennary, trigalactosylated and trisialylated with antennary fucose

p=0,001




GP34 = A4G4S3 - tetraantennary, tetragalactosylated and trisialylated

p=1,59E-10




GP36 = A4S4 - tetraantennary tetragalactosylated and tetrasialylated

p=6,39E-8



GP38 = A4G4S4 - tetraantennary, tetragalactosylated and tetrasialylated



p=7,66E-6




GP39 = A4F1G4S4 - tetraantennary, tetragalactosylated and tetrasialylated with antennary fucose

Rezultati


N-glikani u plazmi:




GP4 = FA2[6]BG1 -biantennary
monogalactosylated with core fucose
and bisecting GlcNAc



GP5 = FA2[3]BG1 -biantennary
monogalactosylated with core fucose
and bisecting GlcNAc




GP10 = FA2G2 -biantennary
digalactosylated with core fucose



GP22 = FA2G2S2 -biantennary digalactosylated
and disialyted with core fucose


Rezultati

N-glikani vezani za IgG:




GP3, GP5, GP6, GP7, GP13,
GP17, GP22

PTSP






GP9, GP14, GP18, GP2







- snažan utjecaj dobi na razinu N-glikana → korekcija ($p=0,05$; korekcija na višestruko testiranje: $p=0,001^*$)

Rezultati



N-glikani vezani za IgG:



GlycoAge test
 $= \log_{10}(FA2/FA2G2)$
 $= \log_{10}(GP4/GP14)$



fiziološka dob
ispitanika s PTSP-om


Zaključak

osobe oboljele od PTSP-a imaju statistički značajno:

- povišene razine N-glikana povezanih s upalnim procesima (Kaneko et al. 2006; Shibata-Koyama et al. 2009)
- povišene razine N-glikana povezanih s preuranjenim starenjem (Knezevic et al. 2009, Dall'Olio et al. 2012)

osobe oboljele od PTSP-a imaju:

- veću vrijednost GlycoAge testa (trend! ↑grupe)



Daljnji ciljevi istraživanja

- ispitati razine N-glikana na preostalim uzorcima PTSP-a i kontrola
- istražiti povezanost razine N-glikana i pojedinih fenotipova PTSP-a (agitacija, psihoza...)
- u bolesnika s PTSP-om i kontrolnih ispitanika potvrditi polimorfizme (12) odabranih gena (6) (FUT8, HNF1A, FUT6/FUT3, SLC9A9, MGAT5 i B3GAT1) koji reguliraju glikozilaciju proteina, određenih GWAS studijama
- procijeniti utjecaj epigenetske regulacije (DNA metilacije) i genske ekspresije HNF1A u bolesnika s PTSP-om i kontrolnih ispitanika

- ispitati nove modele predviđanja stvarne dobi na temelju koncentracije pojedinih N-glikana u plazmi i N-glikana vezanih za IgG
- istražiti promjene N-glikana u animalnim modelima PTSP-a (prof. dr. sc. Dora Zelena, Mađarska akademija znanosti)
- neovisna replikacijska studija (prof. dr. sc. Tanja Jovanovic, Emory University, USA) na 200 ispitanika s PTSP-om (muškarci i žene, civilne žrtve traume-nasilje, silovanja, nesreće...) i 200 zdravih osoba uključenih u Grady Trauma Project (crna i bijela rasa, hispano populacija)

offset project CRO_A-00033

"Technology & Know-how Transfer in Metabolomics and Establishment of Latest Scientific Equipment in Zagreb",


financiran od tvrtke Patria, Finska
(voditelj: prof. dr. Neven Žarković)


Cilj istraživanja

- ispitati razlike u metabolitima kod osoba s dijagnosticiranim PTSP-om (N=350) i zdravih kontrolnih ispitanika (N=350) primjenom neciljane višeplatformske analize metaboloma

Metabolomika


- proučava metabolom- niz spojeva niskih molekularnih težina (metabolita npr. nukleotidi, ugljikohidrati, aminokiseline, lipidi...) koji su rezultat ili su uključeni u metaboličke procese važne za normalno funkcioniranje stanice i cijelog organizma
- metabolički biomarkeri iz urina, krvi i sl. - važni u razjašnjavanju mehanizama bolesti, predviđanju odgovora na lijekove ili prehrambene intervencije ili toksičnih učinaka





- razine metabolita - vrlo osjetljive na genetske, epigenetske i okolišne čimbenike npr. dob, stres, bolest, liječenje, prehrambeni status...
- metabolomika - nadopunjuje "starija" - omics polja kao što su transkriptomika, proteomika i genomika
- personalizirani pristup u medicini

Pristupi u metabolomici: neciljana i ciljana analiza




'Footprinting'

'Fingerpriting'

Profiliranje



Ciljana analiza



- Priprema uzorka Standardi za kvantifikaciju Selektivnost +

+ Nepristranost Obrada podataka -

Tijek rada u metabolomici



Analitičke metode u metabolomici

	NMR	MS		
Princip detekcije	Magnetska svojstva atomskih jezgara (^1H , ^{13}C , ^{31}P)	Odnos mase i naboja ioniziranih čestica		
		LC	GC	CE
Priprema uzorka	+	+	-	+
Reproducibilnost/robustnost	+	-	+	-
Osjetljivost	-	+	+	-
Vrsta komponenti	Polarne i nepolarne	Širok spektar uporabe ovisno o tipu LC-a	Termostabilne i molekule koje isparavaju	Polarne nabijene molekule

Metabolomska istraživanja u psihijatrijskim poremećajima

Redox Biology 14 (2018) 178–186



Contents lists available at ScienceDirect

Redox Biology

journal homepage: www.elsevier.com/locate/redox

Review article

Short overview on metabolomic approach and redox changes in psychiatric disorders

Gordana Nedic Erjavec^{a,b}, Marcela Konjevod^a, Matea Nikolac Perkovic^a, Dubravka Slob Strac^a, Lucija Tudor^a, Coral Barbas^b, Tilmann Grune^c, Neven Zarkovic^d, Nela Pivac^{a,*}

PSYCHIATRIC DISEASE	METABOLOMICS		
	Increased levels ↑	Decreased levels ↓	
Depression	Lysophospholipids Monoglycerophospholipids Phosphatidylethanolamines Glutamate (serum) Aspartate (serum) Alanine Taurine Citrate Formate Glycine Isobutyrate Nicotinate α-KG Succinate Malonate Methylmalonate Succinyl-CoA γ-aminobutyric acid	Acy carnitine Molecules Stearic amide Palmitic amide Lithocholic acid Deoxycholic acid Glycodesoxycholic acid Glycourso-deoxycholic acid Taurochenodeoxycholic acid Glucose Lactate Pyruvate Tryptophan Tyrosine 5-Hydroxyindoleacetic acid (CSF) Homovanillic acid (CSF) N-methylnicotinamide Isoleucine Valine Dopamine Ribulose 5-phosphate Malic acid Fumaric acid	

PSYCHIATRIC DISEASE	METABOLOMICS		
Schizophrenia	Increased levels ↑ Alanine Glycine Valine (urine) Glycine (urine) Lactate Lysophosphatidylcholines Ornithine 3-Indolebutyrate (microflora) Phenylalanine Tyrosine Proline Glutamic acid Pyruvic acid Saturated triglycerides	Decreased levels ↓ Glucose Phosphatidylcholine HDL LDL VLDL Unsaturated fatty acids Lipids Citrate α-KG Creatine Creatinine Acetoacetate 3-Hydroxybutyrate Arginine Glutamine Histidine Ketone bodies Hippurate (microflora) Trimethylamine-N-oxide (microflora)	
PTSD	Glycerophosphoethanolamines (serum) Glycerophospholipids 7α,12α-dihydroxy-3-oxocholest-4-en-26-oic acid	Citric acid (mice) Isocitric acid (mice) Aconitic acid (mice) Succinic acid (mice) Oxalacetic acid (mice) N-acetylglucosamine-6-Phosphate, Palmitoyl ethanolamide Palmitic amide Guanosine Inosine Pantothenic acid 3α-hydroxy-5β-cholan-24-Oic acid Glycocholic acid	
Common metabolites altered in schizophrenia, depression and PTSD.			
METABOLITES	PSYCHIATRIC DISEASE		
	Schizophrenia	Depression	PTSD
Alanine	-	-	ND
α-KG	-	+	ND
Citrate	-	+	- (mice)
Glucose	-	-	ND
Glutamate	+	+	ND
Glycerophospholipids	+	ND	+
Glycine	+	+	ND
Lactate	+	-	ND
Palmitic amide	-	+	+
Pyruvate	+	-	ND
Succinate	ND	+	- (mice)
Tyrosine	+	-	ND
Valine	+	-	ND



+ (increased levels); - (decreased levels); ND (not detected).

Rezultati

'Raw data'


- uzorci plazme 100 ispitanika - 50 ratnih veterana oboljelih od PTSP-a i 50 zdravih kontrolnih ispitanika

- neciljana višeplatformska analiza metaboloma






Rezultati

'Raw data'



Identifikacija










► identificirana 81 komponenta

28 x 81 tablica

Obrada podataka


Normalizacija, skaliranje




Statistička analiza

Multivariantna statistička analiza (SIMCA 14.1)

PCA




PLS-DA




Univarijantna statistička analiza (MATLAB R2015a)

Compound	p value	p value after pBH
2-Deoxy-arabino-hexonic acid, 1,4-lactone	1.25 x 10⁻⁶	8.12 x 10⁻⁵
Aminomalonic acid	0.026192277	0.388454062
pyruvic acid	0.032976896	0.272873017
phosphoric acid	0.041030902	0.388454062
Methionine sum	0.057476969	0.388454062
Unknown sugar 1	0.063492937	0.388454062
Unknown sugar 2	0.068442229	0.388454062
citric acid	0.071976143	0.388454062
lactic acid	0.07418802	0.388454062
Glutamic acid sum	0.087389936	0.388454062
alanine 1	0.091604064	0.388454062
cholesterol	0.10112804	0.388454062
Glycine sum	0.103865585	0.388454062
2-ketoisocaproic acid sum	0.108403445	0.369878546
Tyrosine sum	0.110793438	0.388454062
Phenylalanine	0.118693867	0.388454062
Isoleucine sum	0.119859363	0.388454062
Pentose (D-lyxosylamine / lyxose)	0.121903834	0.388454062
myo-inositol	0.123995121	0.388454062
Proline sum	0.133468588	0.388454062
Leucine sum	0.135414432	0.388454062
palmitic acid	0.137452976	0.388454062
Phenylalanine sum	0.141902131	0.369878546
Pyranose sum	0.147377706	0.399147955
glycerol	0.162293708	0.421963641
Valine sum	0.206933683	0.498173681
oleic acid	0.218482358	0.507191189
glyceric acid	0.23215539	0.520348288
linoleic acid	0.273901801	0.593453903
stearic acid	0.306115525	0.627337325
threonine 2	0.308842991	0.627337325

Compound	p value	p value after pBH
Nonanoic acid	0.33243156	0.654789436
3-Hydroxybutyric acid	0.382868003	0.731953534
Serine sum	0.410894139	0.763089116
tartaric acid	0.446060843	0.783787944
urea	0.446156214	0.783787944
2-ketobutyric acid	0.469261482	0.785857131
Threonine sum	0.471514279	0.785857131
p-cresol	0.484681689	0.787607744
acetoacetate 2	0.498747586	0.790697393
2-hydroxybutyric acid	0.528852169	0.812178773
tryptophan 2	0.539227347	0.812178773
threitol	0.563890353	0.812178773
Unknown 1	0.57324981	0.812178773
pyroglutamic acid	0.57477267	0.812178773
Unknown 2	0.603222438	0.829581137
Creatinine	0.608008541	0.834168292
N-methylalanine	0.616213278	0.834168292
3-indolelactic acid 2	0.616364287	0.829581137
trans-4-hydroxy-L-proline 2	0.628834559	0.834168292
uric acid 1	0.642153093	0.834799022
xylitol	0.670371542	0.854395102
Unknown 4	0.705349038	0.881686298
glutamine 3	0.736285412	0.886269478
oxalic acid	0.755963561	0.893411481
citramalic acid	0.791087446	0.898863957
2-hydroxypyridine	0.8155264	0.898863957
Threonic acid	0.8158919	0.898863957
glycolic acid	0.866455272	0.9253313
Hydracylic/Propanoic acid	0.868387835	0.9253313
gluconic acid 2	0.889298145	0.9323287
Furanose sum	0.908669948	0.937516613
2-Hydroxy-3-methylbutyric acid	0.979095359	0.98163448
2-furoic acid	0.98163448	0.98163448





Daljnji ciljevi istraživanja

- napraviti metabolomsku analizu na preostalim uzorcima PTSP-a i kontrola
- identificirati promijenjene metabolite iz plazme kao potencijalne biomarkere u PTSP-u
- utvrdite nove metaboličke putove uključene u patofiziologiju PTSP-a
- prijenos tehnologije i znanja u metabolomici u primjena najnovije znanstvene opreme u Zagrebu

Hvala na pažnji!

Prof. dr. sc. Nela Pivac, znanstveni savjetnik, Institut Ruđer Bošković, Zagreb, Hrvatska

Dr. sc. Dubravka Švob Štrac, viši znanstveni suradnik, Institut Ruđer Bošković, Zagreb, Hrvatska

Dr. sc. Gordana Nedić Erjavec, viši asistent, Institut Ruđer Bošković, Zagreb, Hrvatska

Dr. sc. Matea Nikolac Perković, viši asistent, Institut Ruđer Bošković, Zagreb, Hrvatska

Lucija Tudor, mag. mol. biologije, asistent, Institut Ruđer Bošković, Zagreb, Hrvatska

Marcela Konjevod, mag. mol. biologije, asistent, Institut Ruđer Bošković, Zagreb, Hrvatska

Doc. dr. sc. Suzana Uzun, Klinika za psihijatriju Vrapče, Zagreb, Hrvatska

Doc. dr. sc. Oliver Kozumplik, Klinika za psihijatriju Vrapče, Zagreb, Hrvatska

Prof. dr. sc. Gordan Lauc i tim iz Laboratorija za glikobiologiju, Genos d.o.o, Zagreb

Prof. dr. sc. Neven Žarković, znanstveni savjetnik, Institut Ruđer Bošković, Zagreb, Hrvatska

Prof. dr. sc. Coral Barbas, The Centre of Metabolomics and Bioanalysis ,University San Pablo, Madrid, Španjolska